MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion [Seeking Alpha]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Seeking Alpha
Summary MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases. Financially, MannKind has strong liquidity but remains burdened by long-term debt obligations and modest net losses. I maintain a "buy" recommendation based on MannKind's solid revenue from Tyvaso DPI and its potential in expanding respiratory treatments. Hiroshi Watanabe/DigitalVision via Getty Images MannKind's Tyvaso DPI Stake Fuels Stock Growth in the PAH Market MannKind Corporation's NASDAQ: MNKD ) stock continues to benefit from its investment in United Therapeutics' ( UTHR ) Tyvaso DPI, which is outperforming in This article was written by Stephen Aye
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]Yahoo! Finance
- MannKind (MNKD) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
MNKD
Earnings
- 11/7/24 - Beat
MNKD
Sec Filings
- 11/19/24 - Form 4
- 11/15/24 - Form 144
- 11/8/24 - Form 4
- MNKD's page on the SEC website